IN THE CLAIMS:

Claims 1-22 (Canceled)

23. (Currently amended) An intranasal formulation ~~comprising~~ consisting of scolpolamine hydrobromide, water, a preservative, glycerin and polyvinyl alcohol, wherein the formulation has a pH of about 3.5, a buffer ~~salt~~ concentration of about 20 mM and wherein the polyvinyl alcohol is present at a concentration of about 10%.

24. (Currently amended) The intranasal formulation of claim 23 wherein the buffer ~~formulation~~ is ~~further~~ comprised of citric acid and sodium citrate.

25. (Currently amended) A method of preventing and/or treating nausea and/or vomiting and/or motion sickness ~~in an individual~~ in a mammal in need thereof ~~comprising~~ consisting of intranasally administering a scolpolamine hydrobromide formulation to said mammal, wherein said formulation ~~is comprised~~ consists of scolpolamine hydrobromide, water, a preservative, glycerin and polyvinyl alcohol, wherein the formulation has a pH of about 3.5, a buffer salt concentration of about 20 mM and wherein the polyvinyl alcohol is present at a concentration of about 10%.

26. (Currently amended) The method of claim 25 wherein the ~~intranasal~~ buffer ~~formulation~~ is ~~further~~ comprised of citric acid and sodium citrate.

27. (New) The intranasal formulation of claim 23 wherein the preservative is benzalkonium chloride.

28. (New) The method of claim 25 wherein the preservative in the formulation is benzalkonium chloride.